Skip to content
DataLookout
Menu

NCT04153149

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

StatusActive, Not Recruiting
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 70 versions: 16 with changes below, 34 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Site details revised at 1 of 121 sites
    • Publications: 14 to 15
  2. Notable Eligibility criteria expanded, about 9 words Show 4 more changesShow less
    • Study completion pushed from Dec 2, 2026 to Jan 13, 2027
    • Study sites: 119 to 121
    • Secondary endpoints: details revised at 6 of 7 entries
    • Publications: details revised at 14 of 14 entries
  3. Minor Study sites: 80 to 119
    • Study completion date: Dec 1, 2026 to Dec 2, 2026
    v68
  4. Minor Study sites: 79 to 80v66
  5. Notable Results first posted: Oct 21, 2025v65
Show 11 earlier versionsHide 11 earlier versions
  1. Minor Secondary endpoints: details revised at 2 of 7 entriesv64
  2. Minor Secondary endpoints: 4 to 7v62
  3. Notable Primary endpoints: 1 to 2
    • Primary completion date changed from estimate of Feb 2024 to May 8, 2024
    • Study completion date: Dec 2026 to Dec 1, 2026
    • Secondary endpoints: 8 to 4
    v53
  4. Minor Primary completion date: Jun 2024 to Feb 2024
    • Study completion date: Jun 2025 to Dec 2026
    v41
  5. Minor Study sites: 80 to 79v37
  6. Minor Study sites: 90 to 80v35
  7. Minor Study sites: 102 to 90v33
  8. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 600 to confirmed 655
    • Study sites: 105 to 102
    v24
  9. Minor Study sites: 104 to 105v23
  10. Minor Study sites: 94 to 104v22
  11. Minor Study sites: 88 to 94v21
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits) in the Overall Population
Timeframe: Up to Month 36
Composite Endpoint of All-Cause Mortality and Recurrent CV Events (CV Hospitalizations and Urgent HF Visits) in the Vutrisiran Monotherapy Subgroup
Timeframe: Up to Month 36

Secondary (7)

Change From Baseline in 6-Minute Walk Test (6-MWT) in the Overall Population
Change From Baseline in 6-MWT in the Vutrisiran Monotherapy Subgroup
Change From Baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) Score in the Overall Population
Change From Baseline in the KCCQ-OS Score in the Vutrisiran Monotherapy Subgroup
All-cause Mortality in the Overall Population and Vutrisiran Monotherapy Subgroup
Show 2 moreShow less
Percentage of Participants With Change in NYHA Class at Month 30 in the Overall Population
Percentage of Participants With Change in NYHA Class at Month 30 in the Vutrisiran Monotherapy Subgroup

Arms and interventions

Vutrisiran 25 mgExperimental

Participants received vutrisiran 25 milligrams (mg) administered subcutaneously (SC) once every 3 months (q3M) during the 36-month double-blind (DB) period. After the DB period, participants continue receiving vutrisiran, 25 mg, SC injection, q3M for up to 24 months in the open-label treatment extension (OLE) period.

PlaceboPlacebo comparator

Participants received vutrisiran matching placebo administered SC q3M during the 36-month DB period. After the DB period, participants receive vutrisiran, 25 mg, SC injection, q3M for up to 24 months in the OLE period.

Drugs: Vutrisiran, Sterile Normal Saline (0.9% NaCl)

Sites

121 sites in 33 countries

United States 17, Japan 14, United Kingdom 8, Germany 7, Poland 6, Spain 6, Australia 5, Portugal 5, Argentina 4, Belgium 4, France 4, South Korea 4, Austria 3, Hungary 3, Israel 3, Netherlands 3, Peru 3, Canada 2, Czechia 2, Denmark 2, Ireland 2, Malaysia 2, Saudi Arabia 2, Colombia 1, Croatia 1, Latvia 1, Lebanon 1, Lithuania 1, Moldova 1, Norway 1, Slovenia 1, Sweden 1, Thailand 1